COVID-19-induced granulomatosis with polyangiitis

BMJ Case Rep. 2021 Mar 18;14(3):e242142. doi: 10.1136/bcr-2021-242142.

Abstract

COVID-19 and granulomatosis with polyangiitis share many clinical and radiological features, making it challenging for clinicians to distinguish between the two. In this case report, we describe a patient who was diagnosed with COVID-19 in October 2020. One month later, she presented with persistent fatigue, shortness of breath and anaemia with worsening renal functions, found to have elevated antineutrophil cytoplasmic antibodies and antiproteinase 3 antibodies, and diagnosed with granulomatosis with polyangiitis.

Keywords: COVID-19; infectious diseases; renal medicine; respiratory medicine; rheumatology.

Publication types

  • Case Reports

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • Biopsy
  • COVID-19 / complications*
  • Diagnosis, Differential
  • Female
  • Granulomatosis with Polyangiitis / diagnosis*
  • Granulomatosis with Polyangiitis / drug therapy
  • Granulomatosis with Polyangiitis / etiology*
  • Humans
  • Immunologic Factors / therapeutic use
  • Kidney / pathology
  • Methylprednisolone Hemisuccinate / therapeutic use
  • Middle Aged
  • Rituximab / therapeutic use
  • SARS-CoV-2

Substances

  • Anti-Inflammatory Agents
  • Immunologic Factors
  • Rituximab
  • Methylprednisolone Hemisuccinate